PDCD1 and glioblastoma: Notably, in an immunotherapy dataset of patients with glioblastoma, PRJNA482620, survival analyses demonstrated a significant prognostic advantage in the low CuproScore group after anti‐PD‐1 immunotherapy (Figure 6G).